Stocktoria
RIGEL PHARMACEUTICALS INC RIGL
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2000-11-29
RIGEL PHARMACEUTICALS INC statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | 42.6% | 13.5% | -17.5% | -46.2% | -8.4% |
| Net margin | 124.7% | 9.8% | -21.5% | -48.7% | -12.0% |
| FCF margin | — | — | — | -61.7% | 3.5% |
| Return on assets | 71.5% | 10.7% | -21.4% | -43.6% | -10.7% |
| Return on equity | 93.8% | 531.8% | 87.6% | 430.2% | -59.0% |
| Debt / equity | 0.13× | 18.25× | -2.09× | -2.94× | 0.66× |
| Current ratio | 2.42 | 2.13 | 1.86 | 1.78 | 2.43 |
| Revenue growth | 64.1% | 53.4% | -2.8% | -19.4% | 37.4% |
Source: SEC EDGAR filings · CIK 0001034842 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.